Skip to main content
. Author manuscript; available in PMC: 2012 Nov 15.
Published in final edited form as: Clin Cancer Res. 2011 Aug 15;17(22):7080–7092. doi: 10.1158/1078-0432.CCR-11-0098

Figure 6.

Figure 6

Effects of Riluzole, Sorafenib and PLX4720 on MAPK pathway and Mcl-1 levels. Western immunoblots examining the effect of A. Riluzole - Ril (10uM), Sorafenib - Sor (5uM) or combination of Riluzole (10uM) and Sorafenib (5uM) on MAPK pathway activation as indicated by levels of ERK phosphorylation in C8161 (B-RAF and N-RAS wild type), UACC903 and 1205Lu (B-RAFV600E) cell lines in vitro. B. Western immunoblots examining the effects of Riluzole (10uM), PLX4720 - PLX (0.05uM) or the combination 10uM and 0.05uM respectively on UACC903 and C8161 cell lines. Samples were normalized to total ERK. NT-No treatment, Veh - Vehicle. C. Western immunoblots examining the effects of Riluzole -Ril (10uM), Sorafenib – Sor (5uM) PLX4720- PLX (0.05uM) on UACC903 and 1205 Lu or 10uM on C8161 or the combination of 10um Riluzole and 5um Sorafenib or 10uM Riluzole and 0.05m PLX4720/10uM PLX4720 on levels of Mcl-1.